$47.77
-0.27-0.56%
At close: -
$47.77
0.001200.00%
After Hours: 4:13 PM EDT
Comments
Loading...
Qiagen Analyst Ratings and Price Targets | NYSE:QGEN | Benzinga
Qiagen Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Qiagen Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
Barclays
Baird
UBS
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Qiagen
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/26/2025 | Buy Now | — | B of A Securities | Derik De Bruin84% | $50 → $53 | Maintains | Buy | Get Alert |
| 06/24/2025 | Buy Now | — | Barclays | Luke Sergott52% | → $55 | Initiates | → Overweight | Get Alert |
| 04/21/2025 | Buy Now | — | Baird | Catherine Schulte66% | $42 → $43 | Maintains | Neutral | Get Alert |
| 04/04/2025 | Buy Now | — | Redburn Atlantic | Ed Ridley-Day5% | — | Downgrade | Buy → Neutral | Get Alert |
| 02/19/2025 | Buy Now | — | Baird | Catherine Schulte66% | $52 → $42 | Downgrade | Outperform → Neutral | Get Alert |
| 02/07/2025 | Buy Now | — | UBS | John Sourbeer34% | $50 → $48 | Maintains | Neutral | Get Alert |
| 01/06/2025 | Buy Now | — | Morgan Stanley | Steve Beuchaw61% | $50 → $48 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 12/10/2024 | Buy Now | — | Jefferies | Tycho Peterson83% | $42 → $54 | Assumes | Hold → Buy | Get Alert |
| 10/17/2024 | Buy Now | — | HSBC | Shubhangi Gupta7% | — | Downgrade | Buy → Hold | Get Alert |
| 08/02/2024 | Buy Now | — | Baird | Catherine Schulte66% | $49 → $52 | Maintains | Outperform | Get Alert |
| 06/27/2024 | Buy Now | — | Wolfe Research | Doug Schenkel72% | → $50 | Upgrade | Peer Perform → Outperform | Get Alert |
| 06/18/2024 | Buy Now | — | JP Morgan | Casey Woodring29% | $52 → $54 | Maintains | Overweight | Get Alert |
| 05/01/2024 | Buy Now | — | Stifel | Daniel Arias78% | $55 → $45 | Maintains | Hold | Get Alert |
| 02/16/2024 | Buy Now | — | Morgan Stanley | Steve Beuchaw61% | $49.48 → $51 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 02/08/2024 | Buy Now | — | JP Morgan | Casey Woodring29% | $50 → $52 | Maintains | Overweight | Get Alert |
| 02/08/2024 | Buy Now | — | Citigroup | Patrick Donnelly80% | $61.86 → $60 | Maintains | Buy | Get Alert |
| 12/20/2023 | Buy Now | — | JP Morgan | Casey Woodring29% | $45 → $50 | Maintains | Overweight | Get Alert |
| 12/19/2023 | Buy Now | — | Wells Fargo | Timothy Daley53% | → $44 | Initiates | → Equal-Weight | Get Alert |
| 12/13/2023 | Buy Now | — | Wolfe Research | Doug Schenkel72% | — | Initiates | → Peer Perform | Get Alert |
| 12/07/2023 | Buy Now | — | Goldman Sachs | Matthew Sykes64% | — | Upgrade | Neutral → Buy | Get Alert |
| 11/02/2023 | Buy Now | — | UBS | John Sourbeer34% | $48 → $42 | Maintains | Neutral | Get Alert |
| 10/17/2023 | Buy Now | — | JP Morgan | Casey Woodring29% | $55 → $50 | Maintains | Overweight | Get Alert |
| 09/26/2023 | Buy Now | — | Citigroup | Patrick Donnelly80% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | Buy Now | — | Baird | Catherine Schulte66% | → $50 | Initiates | → Outperform | Get Alert |
| 08/09/2023 | Buy Now | — | UBS | John Sourbeer34% | $50 → $48 | Maintains | Neutral | Get Alert |
| 02/09/2023 | Buy Now | — | UBS | John Sourbeer34% | $50 → $52 | Maintains | Neutral | Get Alert |
| 02/09/2023 | Buy Now | — | Citigroup | Patrick Donnelly80% | $55 → $60 | Maintains | Buy | Get Alert |
| 11/09/2022 | Buy Now | — | Citigroup | Patrick Donnelly80% | $62 → $55 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Qiagen (QGEN) stock?
The latest price target for Qiagen (NYSE:QGEN) was reported by B of A Securities on June 26, 2025. The analyst firm set a price target for $53.00 expecting QGEN to rise to within 12 months (a possible 10.95% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Qiagen (QGEN)?
The latest analyst rating for Qiagen (NYSE:QGEN) was provided by B of A Securities, and Qiagen maintained their buy rating.
When was the last upgrade for Qiagen (QGEN)?
The last upgrade for Qiagen NV happened on June 27, 2024 when Wolfe Research raised their price target to $50. Wolfe Research previously had a peer perform for Qiagen NV.
When was the last downgrade for Qiagen (QGEN)?
The last downgrade for Qiagen NV happened on April 4, 2025 when Redburn Atlantic changed their price target from N/A to N/A for Qiagen NV.
When is the next analyst rating going to be posted or updated for Qiagen (QGEN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Qiagen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Qiagen was filed on June 26, 2025 so you should expect the next rating to be made available sometime around June 26, 2026.
Is the Analyst Rating Qiagen (QGEN) correct?
While ratings are subjective and will change, the latest Qiagen (QGEN) rating was a maintained with a price target of $50.00 to $53.00. The current price Qiagen (QGEN) is trading at is $47.77, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
